24 completed, 12 terminated, 7 recruiting, 5 not yet recruiting. 60 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 60 | Completed 24, Terminated 12, Recruiting 7, Not yet recruiting 5, Active not recruiting 4, Unknown 4, Withdrawn 4 |
Follow Nevi and Melanomas: new trials by email Literature Review of Nevi and Melanomas trials Research Report on Nevi and Melanomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma Resection of PET (high) and PET (low) Tumors, Lifileucel Manufacturing Clinical v Research, Chemotherapy Regimen - Unresectable or Metastatic Melanoma | Early Phase 1 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 10 | 2026-10-01 | 2026-07-13 |
| A Pilot Study to Examine the Efficacy and Tolerability of Sirolimus on Epidermal Nevi Lesions in Patients 6 Years Old and Above. sirolimus topical gel 0.2% - Epidermal Nevi | Early Phase 1 | Not yet recruiting | Northwestern University | 14 | 2026-10-01 | 2026-09-10 |
| Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study ICI Therapy - Gastrointestinal Neoplasms, Genitourinary Cancer | Early Phase 1 | Not yet recruiting | Indiana University | 80 | 2026-09-01 | 2026-07-15 |
| Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors Methionine-Reduced Diet - Adenocarcinoma, Basal Cell Carcinoma | Early Phase 1 | Recruiting | University of California, Irvine | 25 | 2026-05-01 | 2026-07-31 |
| Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma. Cadonilimab and Recombinant Human Interferon α1b Combination Therapy - Melanoma (Skin Cancer) | Early Phase 1 | Recruiting | Xijing Hospital | 10 | 2025-05-01 | 2026-05-14 |
| A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR) individualized tumor FAST vaccine combination (including adjuvant) - Breast Cancer, Colorectal Cancer, Melanoma | Early Phase 1 | Not yet recruiting | Fengming Kong | 154 | 2025-03-25 | 2025-03-12 |
| FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma Echopulse or Echopulse HD, PolyICLC - Advanced Melanoma | Early Phase 1 | Recruiting | University of Virginia | 11 | 2024-09-27 | 2025-11-20 |
| 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors 177Lu-RAD204 - PDL1 Gene Mutation, Non Small Cell Lung Cancer | Early Phase 1 | Recruiting | Radiopharm Theranostics, Ltd | 30 | 2024-06-03 | 2026-11-02 |
| RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis Vusolimogene oderparepvec (RP1) - Melanoma | Early Phase 1 | Recruiting | Yana Najjar | 25 | 2024-03-07 | 2026-04-13 |
| Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma Ex-vivo expanded allogeneic γδ T cells, Recombinant human interferon α1b, Pembrolizumab - Melanoma | Early Phase 1 | Not yet recruiting | Xijing Hospital | 10 | 2024-01-24 | 2024-01-25 |
| A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors Recombinant oncolytic herpes simplex virus type 1 (R130) - Sarcoma, Carcinoma | Early Phase 1 | Unknown | Shanghai Yunying Medical Technology | 20 | 2023-06-24 | 2023-07-27 |
| Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases Nivolumab, Ipilimumab, Nivolumab + Relatlimab - Metastatic Melanoma, Metastasis to Brain | Early Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 1 | 2023-06-06 | 2026-04-06 |
| Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma CBL0137, Ipilimumab, Nivolumab - Locally Advanced or Metastatic Melanoma | Early Phase 1 | Recruiting | Fox Chase Cancer Center | 12 | 2022-11-30 | 2026-05-22 |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy Exercise, Checkpoint Blockade, Immune - Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma | Early Phase 1 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 22 | 2022-06-21 | 2026-09-15 |
| Zr89 + PET Companion Trial Zirconium Zr 89 Crefmirlimab Berdoxa - Melanoma (Skin) | Early Phase 1 | Active not recruiting | Abramson Cancer Center at Penn Medicine | 6 | 2022-03-08 | 2026-09-21 |
| Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study Recombinant L-IFN adenovirus injection - Head and Neck Cancer, Melanoma | Early Phase 1 | Unknown | Shanghai Fengxian District Central Hospital | 28 | 2021-11-30 | 2022-02-01 |
| CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia MVC-101, Nivolumab, MVC-101 + Nivolumab - Solid Tumour | Early Phase 1 | Withdrawn | Presage Biosciences | 2021-09-15 | 2022-07-08 | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies Rilvegostomig, Volrustomig, Sabestomig - Solid Tumor | Early Phase 1 | Active not recruiting | Presage Biosciences | 15 | 2021-07-26 | 2026-05-22 |
| Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma Encorafenib Pill, Binimetinib Pill, Nivolumab - Melanoma Stage III, Melanoma Stage IV | Early Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 50 | 2021-05-24 | 2026-09-16 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Early Phase 1 | Completed | University of Southern California | 10 | 2021-02-15 | 2024-05-24 |
Showing 20 of 60. Sign in to see all of them.
Melanoma (56) · Breast Neoplasms (10) · Sarcoma (8) · Carcinoma, Renal Cell (5) · Lung Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Head and Neck Neoplasms (4) · Skin Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Brain Neoplasms (3) · Breast Neoplasms, Male (3) · Carcinoma, Hepatocellular (3) · Colonic Neoplasms (3) · Gastrointestinal Neoplasms (3) · Kidney Neoplasms (3)
Neoplasms by Histologic Type (60) · Neoplasms (59) · Neoplasms by Site (58) · Neoplasms, Nerve Tissue (58) · Neuroectodermal Tumors (58) · Neuroendocrine Tumors (58) · Neoplasms, Germ Cell and Embryonal (57) · Skin and Connective Tissue Diseases (56) · Skin Diseases (55) · Skin Neoplasms (52) · Neoplasms, Glandular and Epithelial (14) · Carcinoma (12) · Breast Diseases (11) · Female Urogenital Diseases (10)
Nivolumab (9) · Ipilimumab (6) · pembrolizumab (6) · Interleukin-2 (3) · Magnetic Resonance Spectroscopy (3) · Cyclophosphamide (2) · MART-1 Antigen (2) · Oncolytic Virotherapy (2) · aldesleukin (2) · binimetinib (2) · encorafenib (2) · resiquimod (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Base Sequence (1) · Biopsy (1)
Mayo Clinic (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · Abramson Cancer Center at Penn Medicine (2) · Case Comprehensive Cancer Center (2) · Craig L Slingluff, Jr (2) · Northwestern University (2) · Presage Biosciences (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Pennsylvania (2) · Xijing Hospital (2) · Yale University (2) · Centre Jean Perrin (1) · Columbia University (1) · Cooperative Research Centre for Biomedical Imaging Development (1) · Diwakar Davar (1)
United States (43) · China (4) · Australia (3) · Argentina (1) · France (1) · Germany (1) · Switzerland (1)
Ahmad Tarhini, MD (1) · Amod Sarnaik, M.D. (1) · Amy Paller, MD (1) · Anthony Olszanski, MD (1) · Craig L Slingluff, MD (1) · Craig L. Slingluff, Jr., MD (1) · Diwakar Davar, MD (1) · Elizabeth Gaughan, MD (1) · Evan Lipson, MD (1) · Giorgos Karakousis, MD (1) · Grant McArthur (1) · Haifeng Lin (1) · Hossein Jadvar, MD (1) · J. William Harbour, MD (1)
PMID 22499613, PMID 26330458, PMID 26380086, PMID 26581199, PMID 28360208, PMID 29973204, PMID 32752904, PMID 33955240, PMID 35428211, PMID 35551087, PMID 36923556, PMID 37175874, PMID 37344887, PMID 37377890, PMID 38719544, PMID 39386211, PMID 40135850, PMID 40913745
P30CA015083 (3), 2016 (1), P30CA006973 (1), P30CA014089 (1), P30CA072720 (1), R01CA178846 (1), R21CA259236 (1)